Drug Trial Radar · NCT02723773
A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults
Last checked: Nov 20, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7,539
Actual
Start
Apr 16, 2016
Primary completion
Jun 28, 2023
Study completion Jan 30, 2024
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Mar 30, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study was a long-term follow-up of the two studies 110390 and 113077 (ZOSTER-006/022) to assess the efficacy, safety, and immunogenicity persistence of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine and included an assessment of 1 or 2 additional doses in two subgroups of older adults.
Conditions
- Herpes Zoster
- Herpes Zoster Vaccine
Interventions
Herpes Zoster Vaccine GSK1437173ABiological
Intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Having at Least One Confirmed Herpes Zoster (HZ) Case During the Total Duration of ZOSTER-049:EXT 006-022 Study, OverallTime frame: During the total duration of ZOSTER-049:EXT 006-022 study (From Month 0 to Month 72)
Locations
161 sites in 18 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Spring Valley, California
GSK Investigational Site
Hallandale, Florida
GSK Investigational Site
Boise, Idaho
GSK Investigational Site
Wichita, Kansas
GSK Investigational Site
Columbia, Maryland
GSK Investigational Site
Elkridge, Maryland
GSK Investigational Site
Cary, North Carolina
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Hickory, North Carolina
GSK Investigational Site
Salisbury, North Carolina
GSK Investigational Site
Wilmington, North Carolina
GSK Investigational Site
Winston-Salem, North Carolina
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
Wadsworth, Ohio
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Uniontown, Pennsylvania
GSK Investigational Site
Mt. Pleasant, South Carolina
GSK Investigational Site
Bristol, Tennessee
GSK Investigational Site
San Antonio, Texas
GSK Investigational Site
Newport News, Virginia
GSK Investigational Site
Westmead, New South Wales, Australia
GSK Investigational Site
Wollongong, New South Wales, Australia
GSK Investigational Site
Geelong, Victoria, Australia
GSK Investigational Site
Belo Horizonte, Brazil
GSK Investigational Site
Curitiba, Brazil
GSK Investigational Site
CuritibaPR, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
Victoria, British Columbia, Canada
GSK Investigational Site
Halifax, Nova Scotia, Canada
GSK Investigational Site
Truro, Nova Scotia, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Woodstock, Ontario, Canada
Showing 40 of 161 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.